scholarly journals The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity

2020 ◽  
Vol 11 ◽  
Author(s):  
Maryam Keshtkar-Jahromi ◽  
Ronald B. Reisler ◽  
Jeannine M. Haller ◽  
Denise P. Clizbe ◽  
Robert G. Rivard ◽  
...  
Keyword(s):  
Inactivated Vaccine ◽  
Western Equine Encephalitis

Comparative study between prepared bivalent IB inactivated vaccine and commercial one

2019 ◽  
Vol 36 (2) ◽  
pp. 392-405
Author(s):  
Reda Fathy ◽  
Magda Moustafa ◽  
Kamel Zyan ◽  
Ibrahim ElBorai ◽  
Susan El-Mahdy
Keyword(s):  
Comparative Study ◽  
Inactivated Vaccine

scholarly journals The case for replacing live oral polio vaccine with inactivated vaccine in the Americas

The Lancet ◽  
2020 ◽  
Vol 395 (10230) ◽  
pp. 1163-1166
Author(s):  
Jorge A Alfaro-Murillo ◽  
Marí L Ávila-Agüero ◽  
Meagan C Fitzpatrick ◽  
Caroline J Crystal ◽  
Luiza-Helena Falleiros-Arlant ◽  
...  
Keyword(s):  
Oral Polio Vaccine ◽  
Inactivated Vaccine ◽  
Polio Vaccine

Randomized Trials Comparing Inactivated Vaccine After Medium- or High-titer Measles Vaccine With Standard Titer Measles Vaccine After Inactivated Vaccine

2016 ◽  
Vol 35 (11) ◽  
pp. 1232-1241 ◽  
Author(s):  
Peter Aaby ◽  
Henrik Ravn ◽  
Christine S. Benn ◽  
Amabelia Rodrigues ◽  
Badara Samb ◽  
...  
Keyword(s):  
Randomized Trials ◽  
High Titer ◽  
Inactivated Vaccine ◽  
Measles Vaccine

scholarly journals A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study

Vaccines ◽  
2018 ◽  
Vol 6 (3) ◽  
pp. 47 ◽  
Author(s):  
Raffael Nachbagauer ◽  
Florian Krammer ◽  
Randy Albrecht
Keyword(s):  
Influenza Virus ◽  
Respiratory Tract ◽  
Virus Vaccine ◽  
Influenza Viruses ◽  
Inactivated Vaccine ◽  
Upper Respiratory Tract ◽  
Live Attenuated Vaccine ◽  
Virus Surface ◽  
Virus Challenge ◽  
Attenuated Vaccine

Influenza viruses cause severe diseases and mortality in humans on an annual basis. The current influenza virus vaccines can confer protection when they are well-matched with the circulating strains. However, due to constant changes of the virus surface glycoproteins, the vaccine efficacy can drop substantially in some seasons. In addition, the current seasonal influenza virus vaccines do not protect from avian influenza viruses of human pandemic potential. Novel influenza virus vaccines that aim to elicit antibodies against conserved epitopes like the hemagglutinin stalk could not only reduce the burden of drifted seasonal viruses but potentially also protect humans from infection with zoonotic and emerging pandemic influenza viruses. In this paper, we generated influenza virus vaccine constructs that express chimeric hemagglutinins consisting of exotic, avian head domains and a consistent stalk domain of a seasonal virus. Using such viruses in a sequential immunization regimen can redirect the immune response towards conserved epitopes. In this study, male ferrets received a live-attenuated vaccine virus based on the A/Ann Arbor/6/60 strain expressing a chimeric H8/1 (cH8/1) hemagglutinin, which was followed by a heterologous booster vaccination with a cH5/1N1 formalin inactivated non-adjuvanted whole virus. This group was compared to a second group that received a cH8/1N1 inactivated vaccine followed by a cH5/1N1 inactivated vaccine. Both groups showed a reduction in viral titers in the upper respiratory tract after the A(H1N1)pdm09 virus challenge. Animals that received the live-attenuated vaccine had low or undetectable titers in the lower respiratory tract. The results support the further development of chimeric hemagglutinin-based vaccination strategies. The outcome of this study confirms and corroborates findings from female ferrets primed with a A/Leningrad/134/17/57-based live attenuated cH8/1N1 vaccine followed by vaccination with an AS03-adjuvanted cH5/1N1 split virus vaccine 10.

scholarly journals Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease

2019 ◽  
Vol 20 (6) ◽  
pp. 1256 ◽  
Author(s):  
Mohd Anasir ◽  
Chit Poh
Keyword(s):  
Neutralizing Antibodies ◽  
Enterovirus 71 ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Antigenic Peptide ◽  
Effective Vaccine ◽  
Inactivated Vaccine ◽  
Antigenic Peptides ◽  
Foot And Mouth ◽  
Etiological Agents

Hand, foot, and mouth disease (HFMD) commonly produces herpangina, but fatal neurological complications have been observed in children. Enterovirus 71 (EV-A71) and Coxsackievirus 16 (CV-A16) are the predominant viruses causing HFMD worldwide. With rising concern about HFMD outbreaks, there is a need for an effective vaccine against EV-A71 and CV-A16. Although an inactivated vaccine has been developed against EV-A71 in China, the inability of the inactivated vaccine to confer protection against CV-A16 infection and other HFMD etiological agents, such as CV-A6 and CV-A10, necessitates the exploration of other vaccine platforms. Thus, the antigenic peptide-based vaccines are promising platforms to develop safe and efficacious multivalent vaccines, while the monoclonal antibodies are viable therapeutic and prophylactic agents against HFMD etiological agents. This article reviews the available information related to the antigenic peptides of the etiological agents of HFMD and their neutralizing antibodies that can provide a basis for the design of future therapies against HFMD etiological agents.

Sign in / Sign up

Export Citation Format

Share Document